No impact of dapagliflozin on short-term BP variability in diabetics: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-12-10 05:00 GMT | Update On 2020-12-10 09:48 GMT

Greece: The use of SGLT2 inhibitor dapagliflozin does not affect short-term blood pressure variability (BPV) in type 2 diabetes (T2D) patients, suggests a recent study in the American Journal of Hypertension.

Increased BPV is known to increase the risk of cardiovascular and all-cause mortality in T2D patients. Sodium-glucose-co-transporter-2 (SGLT-2) inhibitors decrease the incidence of death, cardiovascular events, and renal events in this population. This study by Pantelis Sarafidis, University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece, and colleagues aimed to evaluate the effect of dapagliflozin on short-term BPV in T2D patients.

For the purpose, the researchers performed a secondary analysis of a double-blind, randomized, placebo-controlled trial in 85 T2D patients. The subjects were randomized to receive oral dapagliflozin 10mg once daily or placebo for 12 weeks. The patients underwent 24-h ambulatory blood pressure (BP) monitoring with the Mobil-O-Graph NG device at baseline and study-end. With the use of validated formulae for the 24-h and the daytime and nighttime periods, the researchers calculated Standard-deviation (SD), weighted-SD (wSD), coefficient-of-variation (CV), average-real-variability (ARV) and variation-independent-of-mean (VIM).

Key findings of the study include:

Dapagliflozin reduced 24-h brachial BP compared to placebo. From baseline to study-end 24-h brachial BPV indexes did not change with dapagliflozin (SBP-ARV: 11.51±3.45 vs 11.05±3.35; SBP-wSD: 13.59±3.60 vs 13.48±3.33) or placebo (SBP-ARV: 11.47±3.63 vs 11.05±3.00; SBP-wSD: 13.85±4.38 vs 13.97±3.87).
Similarly, no significant changes in BPV indexes for daytime and nighttime were observed in any group.
At study-end, no differences between the groups were observed for any BPV index.
Deltas(Δ) of all indexes during follow-up were minimal and not different between-groups (SBP-wSD: dapagliflozin: -0.11±3.05 vs placebo: 0.12±4.20).

"This study is the first to evaluate the effects of an SGLT-2 inhibitor on short-term BPV in patients with T2DM, showing no effect on dapagliflozin on all BPV indexes studied," concluded the authors.

The study, "Dapagliflozin does not affect short-term blood pressure variability in patients with type-2 diabetes mellitus," is published in the American Journal of Hypertension.

DOI: https://academic.oup.com/ajh/advance-article-abstract/doi/10.1093/ajh/hpaa207/6024653

Article Source : American Journal of Hypertension

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

No impact of dapagliflozin on short-term BP variability in diabetics: Study

Similar News

Once-Weekly Insulin Efsitora Matches Daily Insulin in Type 2 Diabetes Management: NEJM

Good Blood Sugar Control May Lower Risk of Eye Diseases in Older Adults, Study Finds

Lichen Planopilaris Linked to Elevated Risk of Autoimmune, Skin, and Heart Conditions: Meta-Analysis

Fermented Foods During Pregnancy Linked to Reduced Hashimoto’s Risk in Children: Study

SGLT2 Inhibitors Linked to Higher Erythrocytosis Risk Without Increasing Blood Clot Events in Type 2 Diabetes: JAMA

Smoking Increases HS Risk in Type 2 Diabetes Patients, suggests study

Poor Prepregnancy Cardiovascular Health tied to Midlife Heart Risk, Independent of Gestational Diabetes: JAMA

Type 2 diabetes drug improves weight loss, blood sugar in certain Type 1 patients with obesity: Study